Development and Use of Disease-Specific (Reference) Models for Economic Evaluations of Health Technologies: An Overview of Key Issues and Potential Solutions Gerardus W. J. FrederixHossein Haji Ali AfzaliRobyn L. Ward Commentary 01 April 2015 Pages: 777 - 781
Cost Effectiveness of Preventive Treatment for Tuberculosis in Special High-Risk Populations Roland DielNiklas LampeniusAlbert Nienhaus Systematic Review 14 March 2015 Pages: 783 - 809
The Economic Costs of Type 2 Diabetes: A Global Systematic Review Till SeuringOlga ArchangelidiMarc Suhrcke Systematic Review Open access 19 March 2015 Pages: 811 - 831
Nalmefene for Reducing Alcohol Consumption in People with Alcohol Dependence: An Evidence Review Group Perspective of a NICE Single Technology Appraisal Matt StevensonAbdullah PandorMarsha Y. Morgan Review Article 08 April 2015 Pages: 833 - 847
Choice of Outcome Measure in an Economic Evaluation: A Potential Role for the Capability Approach Paula K. Lorgelly Practical Application 11 April 2015 Pages: 849 - 855
Characterizing Heterogeneity Bias in Cohort-Based Models Elamin H. ElbashaJagpreet Chhatwal Original Research Article 08 April 2015 Pages: 857 - 865
A Checklist for Reporting Valuation Studies of Multi-Attribute Utility-Based Instruments (CREATE) Feng XieA. Simon PickardDavid Feeny Original Research Article Open access 31 May 2015 Pages: 867 - 877
Does it Matter Whether Canada’s Separate Health Technology Assessment Process for Cancer Drugs has an Economic Rationale? Jeffrey S. HochJaclyn BecaAnthony L. A. Fields Letter to the Editor Open access 05 May 2015 Pages: 879 - 882
The Silence in Hoch et al.’s Commentary about the Rationale for and Objective(s) of Canada’s Separate HTA Process for Cancer Drugs: The Importance of Transparency and Accountability when Allocating Taxpayers’ Dollars Heather McDonaldCathy CharlesAmiram Gafni Letter to the Editor 07 June 2015 Pages: 883 - 886
